Severity modeling of propionic acidemia using clinical and laboratory biomarkers

Oleg A. Shchelochkov1, Irini Manoli1, Paul Juneau2,3, Jennifer L. Sloan1, Susan Ferry1, Jennifer Myles4, Megan Schoenfeld4, Alexandra Pass1, Samantha McCoy1, Carol Van Ryzin1, Olivia Wenger5, Mark Levin6, Wadih Zein7, Laryssa Huryn7, Joseph Snow8, Colby Chlebowski9, Audrey Thurm9, Jeffrey B. Kopp9, Kong Y. Chen9 and Charles P. Venditti9

PURPOSE: To conduct a proof-of-principle study to identify subtypes of propionic acidemia (PA) and associated biomarkers.

METHODS: Data from a clinically diverse PA patient population (https://clinicaltrials.gov/ct2/show/NCT02890342) were used to train and test machine learning models, identify PA-relevant biomarkers, and perform validation analysis using data from liver-transplanted participants. k-Means clustering was used to test for the existence of PA subtypes. Expert knowledge was used to define PA subtypes (mild and severe). Given expert classification, supervised machine learning (support vector machine with a polynomial kernel, svmPoly) performed dimensional reduction to define relevant features of each PA subtype.

RESULTS: Forty participants enrolled in the study; five underwent liver transplant. Analysis with k-means clustering indicated that several PA subtypes may exist on the biochemical continuum. The conventional PA biomarkers, plasma total 2-methylcitrate and propionylcarnitine, were not statistically significantly different between nontransplanted and transplanted participants motivating us to search for other biomarkers. Unbiased dimensional reduction using svmPoly revealed that plasma transthyretin, alanine:serine ratio, GDF15, FGF21, and in vivo 1-13C-propionate oxidation, play roles in defining PA subtypes.

CONCLUSION: Support vector machine prioritized biomarkers that helped classify propionic acidemia patients according to severity subtypes, with important ramifications for future clinical trials and management of PA.

INTRODUCTION

Propionic acidemia (PA) is an organic acidemia caused by the reduced activity of propionyl-CoA carboxylase (PCC) due to pathogenic variants in PCCA and PCCB. PA is characterized by accumulation of propionyl-CoA-derived metabolites, leading to episodes of metabolic acidosis and multiple organ damage. Affected patients display a range of clinical severity.1-4 The existence of a mild PA phenotype was suggested more than 40 years ago with the description of a “Mennonite Amish” variant of PA, eventually linked to a homozygous c.1606A>G (p.Asn536Asp) variant in PCCB.5,6 However, what constitutes mild versus more severe types of PA, their defining features, such as other genotypes and biomarkers associated with them, has not been established. Propionylcarnitine (C3) and 2-methylcitrate (2-MC) are widely used diagnostic biomarkers to screen presymptomatic newborns for disorders of propionate metabolism,7,8 yet their usefulness to predict the natural history of PA is incompletely understood.4 Liver transplantation in PA aiming to restore hepatic oxidation of propionate created an opportunity to evaluate the performance of C3 and 2-MC pharmacodynamic (response) and, potentially, as surrogate biomarkers. Surprisingly, several studies of the long-term outcomes of liver transplantation in PA revealed that C3 levels before and after the transplant were not significantly different,9-11 prompting questions whether these biomarkers can serve as pharmacodynamic (response) or surrogate biomarkers for PA in a treatment trial.

Identifying biomarkers with predictive characteristics has ramifications for the design of proposed genomic treatments, including messenger RNA (mRNA) and adeno-associated virus–based gene therapy.12 The ability to prognosticate based on biomarker data depends on (1) the availability of a genetically diverse cohort to model the spectrum of PA, (2) sufficient time to track changes in individual patients, and (3) longitudinal measurements of relevant clinical and laboratory parameters. Advances in data science can facilitate identification of predictive biomarkers in an objective fashion, especially in rare diseases like PA, where tests with many dimensions are routinely measured, such as amino acid and acylcarnitine profiles. However, analyses of multidimensional datasets are difficult due to the challenges of identifying complex patterns among categorical and continuous variables that often influence each other nonlinearly.13 Multidimensional phenotyping of a rare disease often leads to datasets characterized by many predictors (p) and few participants (n) (p >> n). This can lead to effect sparsity, i.e., a condition where only some in the large set of predictors actually influence the outcome of interest.15 Support vector machine methods are well suited as “out of the box” solutions for analytical tasks requiring classification and dimensional reduction.15 However, when applied to the field of inborn errors of metabolism, the utility of machine learning has been primarily demonstrated in improving the accuracy of newborn screen calls in datasets composed of hundreds of thousands of participants and a relatively few variables (n > p).16-18

1 Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, MD, USA. 2 NIH Library, Office of Research Services, National Institutes of Health, Bethesda, MD, USA. 3 Zimmerman Associates, Inc., Fairfax, VA, USA. 4 Nutrition Department, Clinical Research Center, National Institutes of Health, Bethesda, MD, USA. 5 New Leaf Center, Mount Eaton, OH, USA. 6 National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. 7 Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, MD, USA. 8 National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. 9 National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 10 email: venditti@mail.nih.gov
Using a relatively small but multidimensional dataset of participants with PA studied through a dedicated natural history protocol (n = 40, p ~ 500), we demonstrate how expert knowledge augmented by machine learning can reveal the existence of clinically relevant subtypes of PA and associated biomarkers. This proof-of-principle paradigm may be extended to other rare diseases, where the number of participants is small, but disease classification is crucial, and discovery of biomarkers is required.

MATERIALS AND METHODS

Definition of outcomes and study design

The primary outcome of interest was to identify classes of propionic acidemia based on the severity of their manifestations and variables associated with each class. A secondary outcome of interest was to identify novel laboratory parameters that can help ascertain classes and serve as candidate pharmacodynamic/response biomarkers or surrogate endpoints. To achieve these outcomes, we used data from a cross-sectional dataset generated through a dedicated natural history study. The cohort of 40 patients was divided into three cohorts: dynamically generated training and test sets composed of nontransplanted PA participants and a validation group (n = 5) composed of participants after a liver transplant. Candidate pharmacodynamic/response biomarkers or surrogate endpoints were identified using severity assignments of three experts augmented using a machine learning algorithm, support vector machine with a polynomial kernel (svmPoly) (See Visual Summary).

Patient cohort and clinical protocols

The clinical research protocol (ClinicalTrials.gov identifier: NCT02890342) was approved by the National Institutes of Health Institutional Review Board prior to the initiation of the study. PA was confirmed through clinical, biochemical, and/or molecular evaluation (Supplemental Table 1). Forty participants enrolled in the study; five underwent liver transplant. Clinical, laboratory, and genetic parameters were studied on all cohort participants (See Supplemental Materials and Methods for more details).

Baseline CO2 production (VCO2) was measured using indirect calorimetry during a resting energy expenditure study.18, 19 13C-propionate was administered orally or as bolus via a gastric or jejunal tube. Breath samples were collected serially. Isotopic ratio mass spectrometry (IRMS, 13C/12C) of CO2 in the expired breath was used to determine the percent 13CO2 recovery over 2 hours (at 30, 60, 120 minutes), and with baseline CO2 production rate, used to calculate propionate oxidation capacity.19,20

Dataset and statistical analysis

The cross-sectional dataset included 40 study subjects, with up to 483 variables ascertained per participant. For participants seen more than once at the NIH Clinical Research Center, the most recent and most complete data were used. Statistical analysis was performed using either GraphPad Prism 8 (GraphPad Software, San Diego, CA) or R (R Foundation for Statistical Computing, Vienna, Austria).21

For machine learning analysis, variables with missing data for >70% of participants were removed; this represented 172 variables. We retained 301 variables. Missing data were imputed using the k-nearest neighbors algorithm (R package VIM, a kNN method)22 and Euclidean distances were normalized using a min–max procedure (a linear transformation of x to y = [y-min]/[max-min]).

The difference in means or medians between two groups was detected using a paired or unpaired Student t-test for normally distributed data and using a Mann–Whitney U test for non-normally distributed data. The comparison of means or medians for three or more groups was assessed using a one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. If the data did not support the assumption of normality, the Kruskal–Wallis test was used followed by the Dunn’s multiple comparisons test. The association between two variables was assessed using a simple linear regression for continuous variables and logistic regression for categorical variables. A p value <0.05 was interpreted as statistically significant. Further distinctions in statistical significance were denoted by *p < 0.01, **p < 0.001, ***p < 0.0001.

RESULTS

Plasma total 2-MC and C3 are affected by declining eGFR

We reasoned that PA participants who received liver transplants may acquire some traits of a biochemically milder form of PA, which can help determine the utility of plasma total 2-MC and C3 to discern the effects of improved propionate metabolism on novel PA biomarkers (Supplemental Fig. 4). We first compared established PA biomarkers, plasma total 2-MC, C3, and other parameters (e.g., eGFR) that can affect these biomarkers, in participants with and without liver transplants. Although there was a trend toward statistical significance (p = 0.13 for 2-MC and p = 0.06 for C3), there was much overlap in values between each group (Fig. 1a, b). We did not detect a difference between available paired pre- and post-liver transplant plasma C3 samples (Fig. 1c). Pretransplant 2-MC was not available. We found no difference in the dosing of levocarnitine between nontransplanted and transplanted participants (Fig. 1d). A statistically significant, but weak, association existed between levocarnitine dose and plasma C3 (Fig. 1e, r = 0.41, p < 0.05). Transplanted participants had a statistically significantly lower creatinine-based, but not cystatin C–based eGFR values (Fig. 1f, g). Association between the estimated eGFR and plasma total 2-MC and C3 was present (Fig. 1h, i; data for creatinine-based eGFR not shown).

Collectively, these data revealed the effect of levocarnitine on plasma C3 and total 2-MC, as well as associations with eGFR. This

Machine learning

To help construct a severity model of PA, 14 clinical and laboratory variables were selected based on their potential to describe the biochemical severity and multiorgan involvement in PA: plasma C3 (umol/L), plasma total 2-MC (nmol/L), full-scale IQ (FSIQ), optic nerve abnormality (absent = 0, present = 1), sensorineural hearing loss (absent = 0, present = 1), height z-score, alanine aminotransferase (ALT, units per liter), peripheral white blood cell count (WBC, k/uL), peripheral red blood cell count (RBC, m/uL), peripheral platelet count (k/uL), left ventricular ejection fraction (LVEF), cystatin C–based estimated glomerular filtration rate (eGFR mL/min/1.73 m2), total protein intake (% of recommended dietary allowance), and incomplete protein intake (% of recommended dietary allowance).

To establish a plausible number of possible clusters in the dataset, which would represent classes of propionic acidemia, we used an unsupervised machine learning approach using k-means clustering. An elbow plot was used to identify the number of possible PA classes. Supervised machine learning was carried out using support vector machine (SVM) with a polynomial kernel function (svmPoly, R package “caret”).23 svmPoly was also used to measure the influence (variable importance) of each parameter on the SVM model of PA.

To enable machine learning using SVM, we first defined the PA disease model as a dimensional space composed of 14 clinical continuous and categorical variables (Supplemental Fig. 1, Supplemental Materials and Methods). A mild or severe PA class was assigned to each participant by three judges with expert knowledge of the natural history of organic acidemias. Each judge was provided with standardized clinical summaries of all nontransplanted PA participants and was asked to classify them as a mild or severe type of PA. Each judge was able to review clinical and laboratory parameters in the NIH electronic medical records, excluding novel biomarkers. Class assignments were then tallied and in cases when judges disagreed in the assigned class, a simple majority was determinative. Interrater agreement analysis is shown in Supplemental Table 3.

As a comparison, we assessed the accuracy of a prototype of the organic acidemia severity scale, originally developed by Walter et al. and updated by Thompson et al. (Supplemental Materials and Methods).24,25 The main metric of each SVM model performance was accuracy, defined as Accuracy = (TP + TN) / (TP + TN + FP + FN), where TP is the number of true positive, TN is the number of true negative, FP is the number of false positive, and FN is the number of false negative prediction. Each svmPoly model was ranked based on its accuracy in predicting judges’ score to identify a model composed of the minimum set of parameters (dimensional reduction) with the highest accuracy (Supplemental Fig. 2). Established and novel biomarkers prioritized by the svmPoly model underwent validation analysis using a dataset composed of liver-transplanted PA participants (n = 5).
may offer a partial explanation (adjusted $R^2 = 0.43$) for why these biomarkers underperformed as response biomarkers and were not significant for liver-transplanted participants. However, we could not exclude the possibility that the inherent severity of PA may also influence plasma C3 and total 2-MC levels. To evaluate the role of PA severity, we conducted a series of machine learning experiments to reveal classes of PA and variables associated with them.

$k$-Means clustering suggested the existence of several PA classes. After defining a PA disease model using 12 clinical and 2 biochemical parameters (Supplemental Fig. 1), we proceeded to identify $k$-clusters among non-liver-transplanted participants. $k$-Means clustering using only clinical parameters did not achieve a nonoverlapping partition of participants (a two-cluster model shown in Fig. 2a, b, Hopkins statistic for cluster tendency = 0.65). $k$-Means clustering using two biochemical parameters achieved partitioning (a three-cluster model shown in Fig. 2c, d, Hopkins statistic = 0.86) with a pattern of grouping based on the concentration of plasma total 2-MC and C3. As expected, a participant homozygous for the previously described “Amish” allele ($\text{PCCB}:\text{c.1606A>G, p.Asn536Asp}$) segregated within a cluster with the lowest levels of plasma total 2-MC and C3 (denoted by an inverted blue triangle within cluster 1 in Fig. 2b, d). Cluster 3 (denoted by green colored squares in Fig. 2d) was composed of two participants whose clinical course included substantial renal...

**Fig. 1** Propionic acidemia (PA) biomarkers, plasma propionylcarnitine and plasma 2-methylcitrate, are associated with levocarnitine dose and eGFR. (a,b) There was no difference in the levels of total plasma 2-methylcitrate (2-MC) and propionylcarnitine (C3) between unpaired transplanted and nontransplanted cohorts. (c) There was no difference in the C3 levels between paired pre- and post-liver transplant samples. (d) Enteral carnitine dosage was not different between transplanted and nontransplanted participants. (e) Plasma C3 and a levocarnitine dosage showed a significant, but modest, association. (f–g) Creatinine-based eGFR was lower in liver-transplanted participants. (h–i) Plasma 2MC and C3 showed significant association with cystatin C–based eGFR. Significant $p$ values are denoted by *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$. 2-MC 2-methylcitrate, C3 propionylcarnitine, Crt-based eGFR creatinine-based estimated glomerular filtration rate, Cys C-based eGFR cystatin C–based estimated glomerular filtration rate, LT liver transplant, n.s. not significant.
involvement, supporting the notion that advanced kidney disease in PA patients constitutes a particular PA subtype. After determining that there could exist two or more subtypes of PA along a biochemical continuum of manifestations, we proceeded to explore clinical and biochemical parameters, or a combination of thereof, that might define these subtypes.

Supervised machine learning can aid in the unbiased selection of novel PA biomarkers

We noted the small number of participants in some classes identified by unsupervised machine learning (e.g., only two participants in cluster 3 as in Fig. 2c, d) and faced the need to increase the variance in parameter spaces to enable supervised machine learning. For this, we used judges’ class assignments of each participant as mild or severe and analyzed clinical and laboratory parameters for their association with a given class (Supplemental Table 4).

We first tested the prediction accuracy using randomly generated classes, mild or severe, assigned to each participant. As expected with the random class assignment, the mean prediction accuracy was 0.5 (Fig. 3a). We then tested a prototype clustering of PA cases using plasma 2-methylcitrate and propionylcarnitine.

Supervised machine learning can aid in the unbiased selection of novel PA biomarkers

We reran svmPoly models, adding one new variable sequentially to the 12 clinical parameters. The new variables were selected from the list of 301 variables with >70% complete data, improving it to 0.8. The combination that yielded the highest mean accuracy (0.98) included plasma C3, ALT, WBC, RBC, cystatin C-based eGFR, and height z-score (sensitivity 0.99 and specificity 0.99, Supplemental Table 5).

After showing that established biochemical PA parameters can improve the prediction accuracy of svmPoly models, we decided to use this approach for an unbiased identification of novel PA biomarkers. We reran svmPoly models, adding one new variable sequentially to the 12 clinical parameters. The new variables were selected from the list of 301 variables with >70% complete data, which was a cutoff selected based on a published review. In this experiment, of all 301 models, a model using plasma C3 ranked 30/301 with mean accuracy of 0.83 and the model using plasma total 2-MC ranked 23/301 with mean accuracy of 0.83.
We therefore first used the mean accuracy of 0.83 as a cutoff to identify novel biomarkers, a level that indicates greater performance than for established diagnostic biomarkers. Thirty models exceeded the cutoff of 0.83 for the mean accuracy. Of these 30 combinations, one used the in vivo 60-minute $^{13}$C-propionate oxidation study and had the mean accuracy of 0.84 (ranked 20/301, Fig. 3a). A model utilizing in vivo 60-minute $^{13}$C-propionate oxidation with the highest mean accuracy (0.96) included five variables ($^{13}$C-Ox 1-13C-propionate oxidation, 2-MC total 2-methylcitrate, C3 propionylcarnitine, FSIQ full scale IQ, LT liver transplant, n.s. not significant, ALT alanine aminotransferase, SNHL sensorineural hearing loss, RBC red blood cells, WBC white blood cells, CysC eGFR cystatin C-based eGFR, LVEF%, percent ejection fraction of left ventricle, %RDA recommended dietary allowance, ONA optic nerve abnormality. Significant p values are denoted by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

For the model including 12 clinical parameters plus 1-13C-propionate oxidation, the three parameters with the highest importance were 1-13C-propionate oxidation (variable importance = 95.7), FSIQ (81.1), and height z-score (78.9) (Fig. 3c). Finally, we performed a longitudinal study to evaluate the effect of the order and the number of study participants required to achieve the mean accuracy of ~0.85 (Fig. 3d). We found that the mean accuracy plateaued after the enrollment of the first 10-15 participants. This suggests that even in a rare disease like PA, the svmPoly modeling could extract relevant features with as few as a dozen participants.

$^{13}$C-propionate oxidation is associated with PA outcomes

After identifying the in vivo 60-minute $^{13}$C-propionate oxidation as one of most impactful variables associated with a PA class defined by judges, we proceeded to validate its association with the 12 clinical parameters in the PA model and 2 biochemical parameters (Fig. 4). 1-13C-propionate oxidation correlated with plasma total 2-
Validation analysis of PA biomarkers using a liver transplant subgroup

We hypothesized that liver transplantation was more likely to be offered to severely affected PA patients and that after transplantation, participants would manifest clinical and biochemical traits of milder PA. To test this hypothesis, we compared values of established and novel biomarkers among severe PA, mild PA, and PA after liver transplant groups. Plasma total 2-MC levels in liver-transplanted participants were not different from either severe or mild PA (Fig. 5a). Plasma C3 in liver-transplanted participants was lower than in severe ($p < 0.01$) but similar to mild PA participants, thus supporting our hypothesis that inherent PA severity can affect the performance of C3 (Fig. 5b).

Plasma transthyretin (prealbumin, ranked 42/301), a biomarker reported to track with renal dysfunction, was higher in severe PA compared to mild participants ($p < 0.05$). Other biomarkers such as platelets, WBC, RBC, LVEF%, Optic Nerve Abnormality, and Sensory Neuron Hearing Loss did not show significant differences across the study groups. However, plasma MC, C3, FSIQ, hearing loss, ALT, height z-score, and the incomplete protein intake as a percent of RDA showed a favorable sensitivity and specificity in identifying cases compared to unaffected controls and good intrasubject reproducibility shown in Supplemental Fig. 3a–c.
than in either the mild PA group (p < 0.01) or PA after liver transplant (p < 0.05, Fig. 5c). Plasma GDF15, elevated in patients with mitochondrial disorders, was ranked only 40/301 based on the mean accuracy of 0.83 as a cutoff to identify novel biomarkers. Although GDF15 differentiated between severe and mild PA, the sample was underpowered to detect the difference in liver-transplanted participants (Fig. 5d). The potential utility of plasma transthyretin, alanineserine ratio, and GDF15 was limited by the significant overlap of values among severe, mild, and liver-transplanted participants. FGF21 ranked 27/301, was significantly lower in mild PA than in severe PA (p < 0.01, respectively), and showed minimal overlap between transplanted and severe PA cases (Fig. 5e). The alanine:serine ratio, which may reflect mitochondrial dysfunction, ranked 8/301 by the svmPoly model. The plasma alanineserine ratio was significantly higher in the severe PA than mild PA (p < 0.01) and liver-transplanted (p < 0.01) participants (Fig. 5f). Finally, in vivo 13C-propionate oxidation in the transplanted cohort, ranked 20/301, was significantly higher than severe (p < 0.001), but no different from mild PA (Fig. 5g). Of note, it was the only examined biomarker, whose values did not overlap between the severe PA group and liver-transplanted participants.

DISCUSSION

The discovery and validation of biomarkers for inborn errors of metabolism have been a challenge due to low incidence, high mortality, medical fragility, ascertainment bias of natural history studies, and interlaboratory variability of biomarker levels. A combination of these factors likely underlies the lack of FDA-accepted validated biomarkers to support new drug and biologics applications for many inborn errors of metabolism, including PA. We aimed to address the need for pharmacodynamic biomarkers and surrogate endpoints to facilitate clinical trials in this patient population, by extending known diagnostic biomarkers, such as plasma 2-methylcitrate, and propionylcarnitine, and integrating them with novel clinical and laboratory parameters such as in vivo 13C-propionate oxidation, and plasma FGF21 and GDF15.

We provide evidence that a polynomial kernel SVM approach can extract relevant features of parsimonious PA models from a dataset with relatively few participants and with many variables (p >> n). We believe that this discovery paradigm can be extended to other rare disease populations. To minimize the problem of overfitting, we supplemented our procedure by performing random repartitioning of the PA dataset into training and test subsets (n = 1,000). The drawback of this approach was
the need for significant computational resources as the number of possible combinations of variables follows an exponential curve (e.g., \( \sim 8,192,000 \) SVM models per one subset composed of 13 variables). We were able to address this limitation by deploying SVM on the local high-performance parallel computing cluster (Biowulf, https://hpc.nih.gov, Supplemental Fig. 2).

The fact that SVM prioritized known diagnostic biomarkers, plasma total 2-methylcitrate and propionylcarnitine, in the top tenth percentile is not surprising. However, the utility of these biomarkers alone to classify PA patients was adversely affected by CKD (Fig. 1h, i), a comorbidity to be considered when selecting PA patients for future clinical trials. The association of the total 2-methylcitrate and propionylcarnitine with renal function prompted us to search for novel biomarkers less affected by CKD. To this end, we selectively reviewed other variables in the top 20th percentile of the ranking order. Among potential biomarkers prioritized by the svmPoly model were plasma transhyretin (ranked 42/301), GDF15 (40/301), FGF21 (27/301), and alanine:serine ratio (8/301). Although transhyretin (prealbumin) has been proposed to serve as an integrated index to assess protein intake in organic acidemias, our previous data revealed a strong association with renal and cardiac function in PA. The ability of alanine:serine ratio to improve the accuracy of svmPoly model was an unexpected finding; however, it fits well with the role of alanine in reflecting impaired oxidation of pyruvate and deficient synthesis of serine, both seen in mitochondrial disorders. GDF15 and FGF21 have been previously proposed as potential biomarkers in propionic acidemia and MMUT-related methylmalonic acidemia. In this study, FGF21 values had minimal overlap among severe, mild, and liver-transplanted PA subjects (Fig. 5e). Transhyretin, GDF15, FGF21, and alanine:serine ratio showed dependence on the cystatin C-based and creatinine-based eGFR (data not shown) and thus their potential utility in clinical trials may not extend to patients with, or at high risk of, advanced CKD. Finally, in vivo 1-13C-propionate oxidation, ranked 20/301, clearly separated liver-transplanted participants from severely affected PA patients, and did not correlate with cystatin C-based eGFR. This suggests that in vivo propionate oxidation may be linked to the residual activity of propionyl-CoA carboxylase activity and has the potential to perform well in clinical assessment of gene or mRNA therapies for propionic acidemia and MMUT-related methylmalonic acidemia.

Limitations of our approach stem from the limited size and the cross-sectional nature of the datasets. First, the liver-transplanted subgroup is small, and as a result, our ability to isolate the effects of immunosuppression on response biomarkers might be limited. While liver-transplanted patients may acquire some traits of mild PA, select organs (e.g., brain, heart, and kidney) are still at risk for long-term complications even after transplant. Whole-body propionate metabolism in transplanted patient is likely distinct from mild PA individuals whose minimal residual activity of PCC may result in tissue-specific protective effects. Therefore, this work will be most relevant to those future clinical trials that aim to utilize response biomarkers in the context of novel therapeutics aiming to restore propionate oxidation in the liver. Second, our enrollment efforts cannot fully capture the effects of antecedent events on the outcomes of PA. For example, some patients may have undergone extensive changes in the diet before they underwent studies via our protocol, thus diminishing our ability to detect the effects of medical foods on growth outcomes. Finally, this study represents only a proof-of-principle approach awaiting validation of this machine learning approach to extracting biomarkers in other rare disease datasets.

In summary, we have demonstrated that subject experts' knowledge supplemented by machine learning can evaluate severity biomarkers in PA. This discovery paradigm could be extended to other rare disorders, where disease classification and discovery of biomarkers are needed but few research subjects are likely to be available.

**DATA AVAILABILITY**

Any materials, data, and datasets produced from or used for this study will be made available upon request.

Received: 27 October 2020; Revised: 26 March 2021; Accepted: 29 March 2021; Published online: 18 May 2021

**REFERENCES**

1. Shchelochkov, O. A., Carrillo, N. & Venditti, C. Propionic Acidemia. (University of Washington, Seattle, 2012).
2. Köller, S. et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J. Inherit. Metab. Dis. 38, 1041–1057 (2015).
3. Köller, S. et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J. Inherit. Metab. Dis. 38, 1059–1074 (2015).
4. Cappuccio, G. et al. Expansion of the phenotypic spectrum of propionic acidemia with isolated elevated propionylcarnitine. JIMD Rep. 35, 33–37 (2017).
5. Kidd, J. R., Wolf, B., Hsia, E. & Kidd, K. K. Genetics of propionic acidemia in a Menonnis Amish kindred. Am. J. Hum. Genet. 32, 236–245 (1980).
6. Gravel, R. A. et al. Mutations participating in interallelic complementation in propionic acidemia. Am. J. Hum. Genet. 55, 51–58 (1994).
7. Matern, D., Tortorelli, S., Oglesbee, D., Gavrilov, D. & Rinaldo, P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J. Inherit. Metab. Dis. 30, 585–592 (2007).
8. Lindner, M. et al. Newborn screening for methylmalonic acidurias-optimization by statistical parameter combination. J. Inherit. Metab. Dis. 31, 379–385 (2008).
9. Pillai, N. R. et al. Liver transplantation in propionic and methylmalonic acidemia: a single center study with literature review. Mol. Genet. Metab. 128, 431–443 (2019).
10. Varra, R. et al. Liver transplantation for propionic acidemia in children. Liver Transpl. 17, 661–667 (2011).
11. Kasahara, M. et al. Living-donor liver transplantation for propionic acidemia. Pediatr. Transpl. 16, 230–234 (2012).
12. Chandler, R. J. et al. Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia. Hum. Gene Ther. 22, 477–481 (2011).
13. Ghosh, S., Dasgupta, A. & Swetapadma, A. A Study on Support Vector Machine based Linear and Non-Linear Pattern Classification. 2019 International Conference on Intelligent Sustainable Systems (ICISS) – 22-24, 28 (IEEE, Conference, Pallada, India, 2019).
14. Donoho, D. & Stodden, V. Breakdown Point of Model Selection When The Number of Variables Exceeds the Number of Observations. The 2006 IEEE International Joint Conference on Neural Network Proceedings 16–21, 1916–1921 (Publisher: IEEE, Vancouver, BC, Canada, 2006).
15. Hastie, T., Tibishirani R. Efficient quadratic regularization for expression arrays. Biostatistics. 5, 329–40. https://doi.org/10.1093/biostatistics/kxu329 (2004).
16. Baumgartner, et al. Supervised machine learning techniques for the classification of metabolic disorders in newborns. Bioinformatics 20, 2985–2996 (2004).
17. Baumgartner, C., Böhm, C. & Baumgartner, D. Modelling of classification rules on metabolic patterns including machine learning and expert knowledge. J. Biomed. Informatics. 38, 89–98 (2005).
18. Chén, W.-H. et al. Web-based newborn screening system for metabolic diseases: machine learning versus clinicians. J. Med. Internet Res. 15, e98–e99 (2013).
19. Hauser, N. S., Manoli, I., Graf, J. C., Sloan, J. & Venditti, C (P) Variable dietary management of methylmalonic acidemia: metabolic and energetic correlations. Am. J. Clin. Nutr. 93, 47–56 (2011).
20. Barshop, B. A. et al. Metabolism of 1-13C-propionate in vivo in patients with disorders of propionate metabolism. Pediatr. Res. 30, 15–22 (1991).
21. R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2013).
22. Kowarik, A. & Temp, M. Imputation with the R Package VM. J. Stat. Softw. 74, 16 (2016).
23. Max Kuhn, Contributions from Jed Wing, Steve Weston A. W., et al. caret: Classification and Regression Training. R package version caret: Classification
Regression Training. R package version 6.0-84. https://CRAN.R-project.org/package=caret (2016).

24. Thompson, G. N. et al. In vivo propionate oxidation as a prognostic indicator in disorders of propionate metabolism. Eur. J. Pediatr. 149, 408–411 (1990).

25. Walter, J. H. et al. Chronic renal failure in methylmalonic acidemia. Eur. J. Pediatr. 148, 344–348 (1989).

26. Beretta, L. & Santaniello, A. Nearest neighbor imputation algorithms: a critical evaluation. BMC Med. Inform. Decis. Mak. 16, 74 (2016).

27. Manoli, I., Pass, A.R., Harrington, E.A. et al. 1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA). Genet Med. https://doi.org/10.1038/s41436-021-01143-8 (2021).

28. Shchelochkov, O. A. et al. Chronic kidney disease in propionic acidemia. Genet. Med. 21, 2830–2835 (2019).

29. Fujita, Y. et al. GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion. 20, 34–42 (2015).

30. Ferreira, C. R. et al. Deoxysphingolipid precursors indicate abnormal sphingolipid metabolism in individuals with primary and secondary disturbances of serine availability. Mol. Genet. Metab. 124, 204–209 (2018).

31. Kakkis, E. D. et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J. Rare Dis. 10, 16 (2015).

32. Yannicelli, S. Nutrition therapy of organic acidaemias with amino acid-based formulas: emphasis on methylmalonic and propionic acidemia. J. Inherit. Metab. Dis. 29, 281–287 (2006).

33. Kirmse, B. et al. Plasma fibroblast growth factor-21 levels in patients with inborn errors of metabolism. Mol. Genet. Metab. Rep. 13, 52–54 (2017).

34. Manoli, L. et al. FGF21 underlies a hormone response to metabolic stress in methylmalonic acidemia. JCI Insight. 3, e124351 (2018).

35. Molema, F. et al. Fibroblast growth factor 21 as a biomarker for long-term complications in organic acidemias. J. Inherit. Metab. Dis. 41, 1179–1187 (2018).

36. Ar, D. et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21, 3548–3558 (2017).

37. Jiang, L. et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat Commun. 21, 11 (2020).

ACKNOWLEDGEMENTS

We thank the patients, families, NIH Clinical Center clinical staff, medical genetics fellows, clinical trainees, postbaccalaureate students, and referring health-care providers for enabling this NIH natural history study. This work utilized the computational resources of the NIH High-Performance Computing (HPC) Blowolf cluster (http://hpc.nih.gov). We are grateful to the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Dental and Craniofacial Research (NIDCR) consult services and trainees from K.Y.C’s lab. This work was supported by the Intramural Research Programs of the National Human Genome Research Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Library/ Zimmerman Associates, NHLBI, National Institutes of Health Clinical Research Center, National Eye Institute, and National Institute of Mental Health (A.T., 1ZICMH002961).

AUTHOR CONTRIBUTIONS

O.A.S. conceptualized the study, supervised the study, provided clinical care, collected and organized research data, performed statistical analyses, performed machine learning experiments, and wrote the paper. I.M. conceptualized the study, provided clinical care, performed data collection, statistical input and edited the paper. P.J. provided statistical input, performed statistical analyses and edited the paper. J.L.S. coordinated the clinical study, collected informed consents from participants, provided genetic counseling, analyzed clinical data, and edited the paper. C.V.R., S.F. provided clinical care, collected informed consents from participants, and edited the paper. A.P. and S.M. performed the isotope breath testing, collected clinical data and edited the paper. O.W. performed recruitment of patients, collection of research data, and edited the paper. J.M., M.S., M.L., W.Z., L.H. provided clinical care, collected research data and edited the paper. A.T., C.C., J.S. performed neurocognitive testing and edited the paper. J.B.K. provided clinical care, statistical input, and edited the paper. K.Y.C. performed and supervised the metabolic cart studies and edited the paper. C.P.V. designed and supervised the clinical research studies and wrote the paper.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS DECLARATION

The clinical research protocol (ClinicalTrials.gov identifier: NCT02890342) was approved by the National Institutes of Health Institutional Review Board prior to the initiation of the study. Written consents have been received and archived for participation/publication from every individual whose data is included.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41436-021-01173-2.

Correspondence and requests for materials should be addressed to C.P.V.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021